Ipsen Announces Updated Indication for Dysport® (abobotulinumtoxinA) for the Treatment of Spasticity in Children

This effort illustrates our continued commitment to patients, helping to ensure children living with cerebral palsy can access the spasticity treatment thats most appropriate for them.